Summit Therapeutics's total assets for Q2 2026 were £752.18M, an increase of 53.10% from the previous quarter. MX:SMMT total liabilities were £122.20M for the fiscal quarter, a 58.10% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.